Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00025545 · ClinicalTrials.gov registry record · Phase 2
Filgrastim-Treated Donor Peripheral Stem Cell Transplantation in Treating Patients With Acute Leukemia</p>
A Phase 2 study, sponsored by Fred Hutchinson Cancer Center.
- Completed
- Registry status
- Phase 2
- Development phase
NCT00025545: Completed Phase 2 study, sponsored by Fred Hutchinson Cancer Center.
NCT00025545 is a Phase 2 study that has completed, run by Fred Hutchinson Cancer Center. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00025545, a Phase 2 study, has completed, sponsored by Fred Hutchinson Cancer Center.
- COMPLETED
- Registry status
- Phase 2
- Development phase
Study Summary
RATIONALE: Transplanted peripheral stem cells can sometimes be rejected by the body's tissues. Treating donor peripheral stem cells with filgrastim may increase the number of donor white blood cells. This may help to decrease the rejection of the transplanted cells in patients receiving them as treatment for acute leukemia. PURPOSE: Phase II trial to study the effectiveness of filgrastim-treated donor peripheral stem cells in treating patients with acute leukemia who are undergoing peripheral stem cell transplantation.
Interventions
- DRUG cyclophosphamide
- RADIATION radiation therapy
- DRUG methotrexate
- PROCEDURE peripheral blood stem cell transplantation
Trial Details
| Field | Value |
|---|---|
| Start Date | 1996-03 |
| Est. Completion | 2002-10 |
| Phase | Phase 2 |
What the finished NCT00025545 record still lists
NCT00025545 is an interventional study that assigns participants to a tested intervention. An enrollment target was not published in the registry record, which is common for early-stage or observational entries.
The record links to 0 conditions, and to 4 interventions - of which cyclophosphamide is the first listed.
NCT00025545 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00025545 about?
NCT00025545 is a clinical study titled "Filgrastim-Treated Donor Peripheral Stem Cell Transplantation in Treating Patients With Acute Leukemia</p>". RATIONALE: Transplanted peripheral stem cells can sometimes be rejected by the body's tissues. Treating donor peripheral stem cells with filgrastim may increase the number of donor white blood cells. This may help to decrease the rejection of the transplanted cells in patients receiving them as trea...
What is the current status of trial NCT00025545?
This trial is currently completed. It is a Phase 2 study. The study started on 1996-03. Estimated completion is 2002-10.
What interventions are being tested in trial NCT00025545?
The interventions under investigation include: cyclophosphamide (DRUG), radiation therapy (RADIATION), methotrexate (DRUG), peripheral blood stem cell transplantation (PROCEDURE).
Who is sponsoring clinical trial NCT00025545?
This trial is sponsored by Fred Hutchinson Cancer Center, which has 483 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia